On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2022.
OSLO, Norway, March 23, 2023 /PRNewswire/ -- On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2022. The Company’s 2022 Annual Report and ESEF file are attached.
The reports are also available on Nordic Nanovector ASA’s website: www.nordicnanovector.com
For further information, please contact:
IR enquiries
Ludvik Sandnes, Interim CEO & CFO
Cell: +47 907 43 017
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. Further information can be found at www.nordicnanovector.com.
The following files are available for download:
| Nanovector Annual Report 2022 | |
| dome-2022-12-31-sv.zip | |
| https://mb.cision.com/Public/9819/3739371/8231ac1a886f9498.pdf | Nanovector Remuneration Report 2022 |
| https://mb.cision.com/Public/9819/3739371/a2a5cbbb40d2a35b.pdf | Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/nordic-nanovector--annual-and-remuneration-reports-approved-301779712.html
SOURCE Nordic Nanovector
Company Codes: Bloomberg:NANOV@NO, ISIN:NO0010597883, Oslo:NANOV, RICS:NANOV.OL, Stockholm:NANOO
